When Promising ALS Treatments Fall Short
Failure in science isn’t the end — it’s data. In a new Nature spotlight, Packard Center Founder and Executive Director, Dr. Jeffrey Rothstein reflects on the phase I failure of BIIB078, a promising ALS gene therapy that performed flawlessly in the lab but produced the opposite result in patients. His takeaway: even a trial that doesn’t work teaches us something vital — and for Rothstein, that lesson is already driving the next experiment.